


Figure 1

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7






Figure 8



b

- Anti-IP-10 (n=4)
- ▲ Anti-VEGF (n=6)
- Anti-VEGF + anti-IP-10 (n=5)



c

- IP-10 $^{-/-}$ into BALB/c: Control Serum (n=6)
- ▲ B6 into BALB/c: Anti-VEGF (n=6)
- IP-10 $^{-/-}$ into BALB/c: Anti-VEGF (n=6)






Figure 9



10A



10B




Figure 10

Figure 11

//A




//B



Figure 12

12A

Serum creatinine in the untreated mice after
kidney ischemia reperfusion



12B

Serum creatinine in PTK 787 treated mice after
kidney ischemia reperfusion






Figure 12

12c

**Serum creatinine in MMF treated mice
after kidney ischemia reperfusion**

12D

**Serum creatinine in MMF & PTK 787 treated mice
after kidney ischemia reperfusion**

Serum alanine aminotransferase (ALT)

90 min of hepatic warm ischemia followed by 6 h of reperfusion

13A

Serum ALT (U/L)	
Control Ab	Anti-VEGF Ab
6008	423
4464	200
2564	290
1706	934
3352	567
	63
MEAN	3618.8
SEM	750.5
	412.8
	126.3

13B

